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A B S T R A C T
Background: Leptin and adiponectin are adipose-tissue derived hormones primarily involved in glucose, lipid,
and energy metabolism, inflammation, and atherosclerosis. Both adipokines may cross the blood-brain barrier
but evidence on their roles in cognitive impairment is limited and conflicting. Here, we determined associations
of plasma adipokine concentration with cognitive impairment in older adults.
Methods: Cross-sectional analysis of baseline data from 669 participants aged ≥65 years of the Biomarker
Development for Postoperative Cognitive Impairment in the Elderly (BioCog) study were recruited 2014–2017 at
study sites in Berlin, Germany and Utrecht, the Netherlands. Cognitive impairment was defined as the lowest
tertile of a cognitive summary score derived from six neuropsychological tests.
Results: After adjustment for age, sex, fasting, BMI, diabetes, hypertension, cerebrovascular disease, and cor-
onary heart disease, higher leptin concentrations and a higher leptin/adiponectin ratio (LAR) were associated
with a higher odds of cognitive impairment (OR per 1 SD higher leptin concentration, 1.33; 95 % CI 1.05, 1.69;
p= 0.02; OR per 1 SD higher LAR, 1.26; 95 % CI 1.01, 1.57; p=0.04). Sensitivity analyses determined that
these findings were driven by the non-obese group (BMI < 30 kg/m2), whereas leptin and LAR were not as-
sociated with cognitive impairment in the obese group (BMI≥ 30 kg/m2). Soluble leptin receptor, leptin/soluble
leptin receptor ratio, total adiponectin and high-molecular weight adiponectin concentrations were each not
associated with impairment.
Conclusions: With leptin as a known promoter of atherosclerosis and inflammation, our findings point to a pa-
thogenic role of leptin in age-related cognitive impairment that may be limited to non-obese individuals and
warrants further investigation.
1. Introduction
The adipokines leptin and adiponectin are secreted by adipocytes
and contribute to metabolic homeostasis (Grassmann et al., 2017;
Lopez-Jaramillo et al., 2014; Nimptsch et al., 2019; Stern et al., 2016)
but have opposing effects on vascular function and inflammation.
Leptin (which circulates at levels proportional to adipose tissue mass
and is thus a signal for adiposity (McGuire and Ishii, 2016)) promotes
atherosclerosis, endothelial dysfunction and inflammation. In contrast,
adiponectin (which circulates at levels inverse to adipose tissue mass
(Aleksandrova et al., 2018)) has vascular health-promoting, anti-in-
flammatory and insulin-sensitizing properties (Grassmann et al., 2017;
Nimptsch et al., 2019). Both adipokines may cross the blood-brain
barrier (BBB) (Adya et al., 2015; Bloemer et al., 2018) (though the
evidence on adiponectin is conflicting (Forny-Germano et al., 2018)),
and may influence cerebrovascular function and neuroinflammation
(Adya et al., 2015; Forny-Germano et al., 2018). Effects of leptin and
adiponectin on the pathogenesis of cognitive impairment could thus be
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expected. Nonetheless, epidemiological investigations on their asso-
ciations with cognition are often limited by small sample size and a
focus on patient populations (Gustafson et al., 2015; Labad et al., 2012),
children (Buck et al., 2019; Li et al., 2019) or younger adults (Bove
et al., 2013) and they have produced mixed results (e.g., Albala et al.,
2016; Bednarska-Makaruk et al., 2017; Bove et al., 2013; Cezaretto
et al., 2018; Gilbert et al., 2018; Gunstad et al., 2008; Gustafson et al.,
2012, 2015; Holden et al., 2009; Kitagawa et al., 2016; Labad et al.,
2012; Lieb et al., 2009; Oania and McEvoy, 2015; Sang et al., 2018;
Warren et al., 2012). For instance, reports of an inverse relationship of
leptin concentration with cognitive function (Gunstad et al., 2008;
Gustafson et al., 2015; Labad et al., 2012 Gorska-Ciebiada et al., 2016)
are contrasted with studies implicating higher leptin concentration or
higher leptin bioavailability (indicated by lower levels of its soluble
receptor, sOB-R; (Gruzdeva et al., 2019)) in reducing cognitive risk
(Albala et al., 2016; Gilbert et al., 2018; Holden et al., 2009; Khemka
et al., 2014; Lieb et al., 2009; Yin et al., 2018) as well as null results
(Bednarska-Makaruk et al., 2017). Similarly, whereas some reported a
positive correlation of adiponectin with cognitive test performance
(Cezaretto et al., 2018; Teixeira et al., 2013), others found a higher
adiponectin concentration in patients with dementia compared with
healthy or less severely impaired controls (Bednarska-Makaruk et al.,
2017; Gilbert et al., 2018; Khemka et al., 2014) or inverse associations
with cognitive function (Sanz et al., 2019).
Of note, adiponectin occurs in trimer, hexamer, and multimeric
(high–molecular weight, HMW) form of which the latter appears to be
biologically particularly active (Aso et al., 2006). Only a few studies
have measured HMW adiponectin (Arnoldussen et al., 2018; Gustafson
et al., 2015; Kitagawa et al., 2016) but surprisingly found no association
with cognition despite the fact that adiponectin-induced improvement
in cerebrovascular function and neuroinflammation would likely de-
pend on the biological activity of the compound. Clarification of the
roles of total versus HMW adiponectin in cognition is therefore needed.
Here, our goal was to determine the associations of leptin and its
receptor, and of total and HMW adiponectin with cognitive impairment
in a large sample of older adults. To operationalize the antagonistic
effects of leptin and adiponectin, we additionally calculated the leptin/
adiponectin ratio as an ‘atherosclerotic index’ that has previously been
shown to correlate with metabolic health (Finucane et al., 2009) and
health outcomes (Park et al., 2013) as well as the leptin/sOB-R ratio as
an index of free, unbound leptin in circulation (Herrick et al., 2016).
2. Materials and methods
2.1. Study design
We used a cross-sectional study design based on data from the
Biomarker Development for Postoperative Cognitive Impairment in the
Elderly (BioCog) study, an observational study on post-operative cog-
nitive impairment. The full study protocol has been reported elsewhere
(Winterer et al., 2018). In brief, BioCog recruited 1033 participants in
Berlin, Germany, and Utrecht, the Netherlands, who were ≥65 years
old, scheduled for elective surgery of any type (expected duration
≥60min), were Caucasian, free of clinical dementia (Mini Mental State
Examination, MMSE≥ 24 (Folstein et al., 1975)), and had no history of
neuropsychiatric disease or addiction disorder. Only baseline data
collected during the days before surgery were used.
2.2. Ethical consideration
The BioCog study has full institutional ethical approval at Charité
Universitätsmedizin Berlin (EA2/092/14) and UMC Utrecht (No. 14-
469), and is registered on clinicaltrials.gov (NCT02265263).
Assessments complied with the Declaration of Helsinki and participants
provided informed consent.
2.3. Clinical assessment
Sociodemographic data and medical history including history of
hypertension, diabetes, coronary heart disease (CHD), transient is-
chemic attack (TIA) and stroke were ascertained using a combination of
self-report and clinical records. Current smoking and level of education
were self-reported. Height and weight were measured to derive body
mass index (BMI). Obesity was defined as BMI≥ 30 kg/m2.
Underweight was defined as BMI < 18.5 kg/m2 (NCD Risk Factor
Collaboration, 2016).
2.4. Adipokine measurement
Blood was collected on the day of surgery in a supine position,
following an overnight fast and before incision, and was centrifuged
after 30−40min at room temperature at 2500 x g for 10min to obtain
serum. Plasma was collected into ethylenediaminetetraacetic acid
(EDTA) tubes which were placed on a rocking mixer for at least 30 s for
anticoagulation and was centrifuged at 2500 x g for 10min. Samples
were frozen at -80 °C, and following a single thaw/refreeze cycle, were
shipped from a central coordinating lab to analysis laboratories for
measurement of leptin and receptor (sOB-R) and of total adiponectin
and HMW adiponectin from plasma. For logistical reasons, leptin and
sOB-R were measured at two laboratories (37 % of samples at Lab 1; 63
% at Lab 2). Allocation of samples to labs was unrelated to study site,
outcome or any other potentially confounding factor. The first sets of
samples arriving at the central lab were allocated to Lab 1 and later
samples to Lab 2. Both labs used identical ELISA kits (BioVendor GmbH,
catalogue # RD191001100 for leptin; catalogue # RD194002100 for
sOB-R). Total and HMW adiponectin were measured at a single la-
boratory (Lab 2) using a kit manufactured by Alpco (Salem, USA; cat-
alogue # 47-ADPHU-E01). Assays were performed according to the
manufacturers’ protocols. Mean intra-assay coefficients of variation
(CV) for pool plasma (controls) were 6.43 % for total adiponectin and
7.41 % for HMW adiponectin; inter-assay CV were 12.51 % and 14.09
% respectively. Mean intra-assay CV were 3.39 % (Lab 1) and 2.45 %
(Lab 2) for leptin, and 4.81 % (Lab 1) and 3.63 % (Lab 2) for sOB-R.
Inter-assay CVs were 11.03 % (Lab 1) and 2.63 % (Lab 2) for leptin and
4.76 % (Lab 1) and 4.28 % (Lab 2) for sOB-R. Measurements which
were below or above the limits of quantification were set as the re-
spective lower or upper limit of quantification (leptin, n= 22; sOB-R,
n=6; HMW adiponectin, n= 1 across both labs). For a small number
of samples, Lab 2 additionally produced values that were outside of the
limits of quantification (leptin, n= 22; total adiponectin, n= 2; sOB-R,
n=1). These were included as those measured values for the purpose
of this analysis. We derived the leptin/adiponectin ratio (LAR) and the
leptin/sOB-R ratio (free leptin index; FLI). Additionally, plasma C-re-
active protein (CRP) and interleukin-6 (IL-6) were measured.
2.5. Cognitive examination
Participants performed six age-sensitive neuropsychological tests
tapping the domains of processing speed, executive function and verbal
and non-verbal memory during the days before surgery. Four tests
(Paired Associates Learning; Verbal Recognition Memory; Spatial Span;
Simple Reaction Time) were from the Cambridge Neuropsychological
Test Automated Battery (CANTAB®; Cambridge Cognition Ltd.) and two
were conventional tests (Grooved Pegboard; Trail-Making Test-B).
From performance on those six tests, the latent ‘g’ factor was calculated
as an index of participants’ global cognitive ability (Spearman, 1904) as
reported in detail elsewhere (Feinkohl et al., 2019). Use of g is ad-
vantageous, because it reflects only the variance shared by all six
cognitive tests; thus it is immune to test-specific measurement error and
so interpretations of analyses based on g may have higher reliability
compared with analyses of observed test scores (Penke and Deary,
2010). G is a standardized score with mean 0 and standard deviation 1
I. Feinkohl, et al. Psychoneuroendocrinology 120 (2020) 104783
2
in the total sample. Here, we defined cognitive impairment as the
lowest g tertile. We have previously cross-validated this definition of
cognitive impairment with the more commonly used cognitive
screening instrument Mini-Mental State Examination (MMSE) (Folstein
et al., 1975) by showing that MMSE scores were lower in the lowest g
tertile compared with the upper tertiles (Feinkohl et al., 2019).
2.6. Statistical analysis
669 participants had complete data on sociodemographic and cog-
nitive parameters, and on leptin and HMW adiponectin, and provided
our analysis sample. Data on total adiponectin were missing for n= 1
and on sOB-R for n= 25 participants.
Participants were divided into quartiles based on the distribution of
each adipokine. Characteristics were compared across quartiles using
analyses of variance (ANOVA) for continuous variables and chi2 tests
for categorical variables. The associations of each adipokine with one
another and with age and BMI were examined in univariate Spearman
rank correlation analyses.
Multiple logistic regression analyses determined the association of
quartiles of each adipokine with the odds of cognitive impairment using
the lowest quartile as the reference category. In addition, we estimated
the odds ratio associated with a 1 standard deviation higher adipokine
concentration on a continuous scale. In the respective first model
(Model 1) we adjusted for age, sex, fasting status and (for analyses of
leptin, sOB-R, LAR, FLI) for analysis lab. Model 2 additionally adjusted
for BMI, diabetes, hypertension, CHD, TIA and stroke. To test for non-
linearity, we subsequently added quadratic terms to the multivariable
models (Model 2) of adipokines as continuous parameters. Finally,
multivariate models (Model 2) of continuous adipokines were repeated
with additional adjustment for CRP, IL-6, education and smoking, and,
separately, with exclusion of underweight participants. For those adi-
pokine exposures with statistically significant results in Model 2, mul-
tiple linear regression analyses additionally explored their associations
with scores on the six individual cognitive tests used to generate g.
In post-hoc analyses, we repeated all multivariable models (Model
2) associating continuous adipokines with odds of cognitive impairment
stratified by obesity status (BMI < 30 versus ≥30 kg/m2), and across
the total sample tested for effect modification by including interaction
terms (adipokine x BMI). In cases where information was missing on a
covariate, we assigned the respective covariate as ‘absent’ (hyperten-
sion, n= 13; diabetes, n= 13; stroke, n=16; CHD, n=18; TIA,
n=19; smoking n=16). Missing data on CRP were replaced by the
median of the distribution (n= 6). Missing data on education were not
imputed (n= 53). Data on all remaining variables were complete.
3. Results
3.1. Sample characteristics
Participants were aged between 65 and 90 years (mean 72.2 ± 4.9
years) and ten participants were not fasted. Those with high leptin
concentrations as compared to those with low concentrations had
higher BMI, were more likely to have a history of hypertension and
diabetes, and less likely to be male and to have a history of CHD
(Table 1). Participants with high as compared to those with low adi-
ponectin concentrations had a lower BMI, were older, less likely to be
male, and less likely to have a history of hypertension, diabetes, and
CHD (Table 2). The covariate structure according to quartiles of sOB-R
and HMW adiponectin is shown in Supplemental Tables S1 and S2.
In correlation analyses, leptin concentrations were positively cor-
related to BMI and inversely associated with sOB-R (Table 3). sOB-R
was inversely correlated to BMI, modestly positively correlated with
total and HMW adiponectin, and weakly positively correlated with age.
Total and HMW adiponectin were inversely correlated with BMI and
weakly positively associated with age. Total adiponectin was highly
correlated with HMW adiponectin.
3.2. Adipokines and cognitive impairment
In multiple logistic regression analyses, we found that higher
quartiles of leptin and higher quartiles of LAR were each associated
with higher odds of cognitive impairment (Table 4). The association for
leptin but not for LAR remained following multivariable adjustment
(Model 2). For instance, participants in the highest quartile of leptin
concentration were at 2.9-fold increased odds of impairment relative to
the lowest quartile (OR 2.86; 95 % CI 1.43, 5.72). Quartiles of sOB-R,
total and HMW adiponectin, and FLI were unrelated to cognitive im-
pairment throughout (Table 4).
Next we assessed the adipokines as continuous parameters in further
multiple logistic regression analyses. Higher leptin concentration and
higher LAR were each associated with increased odds of cognitive im-
pairment (Table 4). Each standard deviation higher leptin and each
standard deviation higher LAR were associated with 1.30-fold (OR
1.30; 95 % CI 1.07, 1.57) and 1.28-fold (OR 1.28; 95 % CI 1.07, 1.54)
increased odds of cognitive impairment, respectively, with age, sex,
fasting and analysis lab controlled for. In absolute numbers, each 1 ng/
mL higher leptin concentration was associated with a 0.9 % higher odds
of impairment (OR 1.01; 95 % CI 1.00, 1.02). These results were un-
changed following multivariable adjustment in Model 2 (for leptin, OR
per 1 standard deviation increment 1.33, 95 % CI 1.05, 1.69; for LAR,
OR per 1 standard deviation increment in LAR 1.26, 95 % CI 1.01,
1.57). Addition of quadratic terms did not produce statistically sig-
nificant estimates (quadratic term for leptin, P=0.11; quadratic term
for LAR, P=0.41) indicating that non-linearity did not underlie the
aforementioned associations. Quadratic terms for all of the remaining
adipokines were also statistically non-significant (sOB-R, P=0.54;
total adiponectin, P=0.10; HMW adiponectin, P=0.12; FLI,
P=0.07).
Addition of CRP, IL-6, education and smoking into the respective
Model 2, or exclusion of seven underweight participants, did not
change any of the results (data not shown). Associations of leptin and
LAR with cognitive impairment appeared to be driven by the timed tests
of processing speed and executive function (Simple Reaction Time,
Grooved Pegboard, Trail-Making Test-B), as trends were observed for
higher leptin and higher LAR associated with slower performance on
these tests (Supplemental Table S3).
3.3. Sensitivity analyses
BMI was not associated with cognitive impairment in any of the
multivariable models presented above and in Table 5 (data not shown;
all P > 0.20) and in analyses controlling only for age and sex (OR per 1
kg/m2 increment 1.03; 95 % CI 0.99, 1.07; P=0.16), but due to its
close relationship with adipokine concentrations we explored a poten-
tial interaction of adipokines with BMI in determining odds of cognitive
impairment. As a first step, the respective Model 2 with adipokines as
continuous parameters were repeated separately for obese
(BMI≥30kg/m2) and non-obese participants (BMI < 30 kg/m2;
Table 5). In the non-obese group, higher leptin (OR per 1 standard
deviation increment 2.09, 95 % CI 1.44, 3.02), higher LAR (OR per 1
standard deviation increment 1.72, 95 % CI 1.23, 2.41), lower sOB-R
(OR per 1 standard deviation reduction 1.28, 95 % CI 1.01, 1.61) and
higher FLI (OR per standard deviation increment 1.54, 95 % CI 1.03,
2.30) were each associated with higher odds of cognitive impairment.
There were no findings for the obese group (all P > 0.20; Table 5). As a
second step, we repeated the analyses across the total sample with
addition of adipokine x BMI interaction terms. Differential relationships
with cognitive impairment according to BMI were indicated by inter-
action terms for leptin (multivariable-adjusted P=0.002), LAR (mul-
tivariable-adjusted P=0.03) and FLI (multivariable-adjusted P=0.05;
Table 5).
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4. Discussion
We found in a sample of older adults that higher levels of total
(bound and unbound) leptin and a higher leptin/adiponectin ratio
(LAR) were each associated with higher odds of being cognitively im-
paired. The associations were independent of sociodemographics, vas-
cular risk factors, macrovascular disease and inflammation as well as
BMI. Neither total nor HMW adiponectin alone were associated with
impairment. Our data overall suggest that higher leptin concentrations
are related to a higher odds of cognitive impairment, while they do not
support the hypothesis that adiponectin concentrations are related to
this outcome.
Metabolic dysregulation and obesity are candidate risk factors for
age-related cognitive impairment (Pedditizi et al., 2016; Van den Berg
et al., 2009), but fewer studies have evaluated adipokine concentrations
as potential contributors to the relationship.
Previous investigations had reported a higher level of adiponectin as
a correlate of higher cognitive function in middle-aged (Cezaretto et al.,
2018) and older adults (Teixeira et al., 2013) and lower adiponectin in
patients with mild cognitive impairment or Alzheimer’s disease (AD)
compared with controls (Teixeira et al., 2013;Gorska-Ciebiada et al.,
2016). In direct contrast, others implied higher adiponectin as asso-
ciated with presence ofcognitive impairment (Bednarska-Makaruk
et al., 2017; Gilbert et al., 2018; Khemka et al., 2014 Sanz et al., 2019
Wennberg et al., 2016) . Here, we found no relationship of adiponectin
with cognition even with minimal adjustment and are thus unable to
resolve this inconsistency.
Higher circulating leptin had previously been associated with a re-
duced cognitive risk in a number of epidemiological investigations
(Gilbert et al., 2018; Holden et al., 2009; Johnston et al., 2014; Khemka
et al., 2014; Lieb et al., 2009; Littlejohns et al., 2015; Zeki Al Hazzouri
et al., 2013;Yin et al., 2018). Such reports appear counterintuitive in
the face of leptin as a promoter of atherosclerosis, endothelial dys-
function and inflammation, but can be explained by an additional role
of leptin as a cognitive enhancer. Leptin receptors are expressed in
several regions of the brain, where it not only acts as a satiety signal
(Banks et al., 2006; Letra et al., 2014), but is also involved in neuro-
genesis and brain growth (Banks et al., 2006), the clearance of beta
amyloid (a neuropathological hallmark of Alzheimer’s disease) (Fewlass
et al., 2004), and in hippocampal synaptic plasticity (Forny-Germano
et al., 2018; McGregor and Harvey, 2018).
Yet, in our analysis, and in several other studies of older adults,
higher leptin was associated with cognitive impairment (Gorska-
Ciebiada et al., 2016; Gunstad et al., 2008; Labad et al., 2012). For
instance, in male participants of the Edinburgh Type 2 Diabetes Study
(ET2DS) after controlling for a range of covariates including age, BMI,
waist-hip ratio, estimated pre-morbid cognitive ability, inflammation,
vascular risk factors and macrovascular disease, higher plasma leptin
was associated with a lower global cognitive function and with a poorer
performance on a verbal fluency test and the Trail-Making Test-B as a
measure of processing speed and executive function (Labad et al.,
2012). Here, we observed a trend for poorer performance on this test as
associated with higher leptin concentration albeit the trend fell short of
statistical significance and was of smaller effect size compared with
ET2DS results. In any event, associations of higher leptin with cognitive
impairment are corroborated by reports of associations of higher leptin
concentration with brain atrophy (Rajagopalan et al., 2013) and may
reflect the aforementioned beneficial effects of leptin on brain function
being outweighed by its effects on atherosclerosis, endothelial dys-
function and inflammation (Forny-Germano et al., 2018). Although in
our analysis the association of leptin with cognitive impairment re-
mained after adjustment for CRP and IL-6, speaking against mediation
Table 1
Characteristics of total study sample and by quartiles of leptin.
Total sample Leptin P-value
Quartile 1 Quartile 2 Quartile 3 Quartile 4
N 669 166 164 174 165
Leptin concentration, range, ng/mL 0.2–159.9 0.2 – 5.7 5.8 – 13.4 13.4 – 30.6 30.7 – 159.9
Age, years, mean 72.2 72.7 71.9 72.2 71.8 0.33
Male sex, % 58.3 % 84.3 62.2 52.3 34.5 <0.001
Body mass index, kg/m2, mean 27.0 24.2 26.6 27.3 30.1 <0.001
Hypertension, % 61.6 55.4 56.7 58.6 75.8 <0.001
Diabetes, % 20.2 13.3 20.7 17.8 29.1 0.003
Coronary heart disease, % 18.4 25.3 18.9 14.9 14.5 0.04
Stroke, % 4.8 4.8 4.9 5.2 4.2 0.98
Transient ischemic attack, % 3.3 4.2 3.0 2.3 3.6 0.78
Cognitive impairment, % 33.3 22.0 23.4 23.8 30.2 0.06
Precise range is not shown due to rounding. N=669. P-value for comparison among leptin quartiles in analyses of variance (ANOVA) or chi2 tests.
Table 2
Characteristics of study participants by quartiles of total adiponectin.
Total adiponectin P-value
Quartile 1 Quartile 2 Quartile 3 Quartile 4
N 174 167 168 159
Adiponectin concentration, range, ng/μL 2.7 – 9.0 9.1 – 12.7 12.8 – 18.0 18.0 – 61.1
Age, years, mean 71.2 72.4 72.2 72.8 0.02
Male sex, % 70.1 60.5 54.2 47.2 <0.001
Body mass index, kg/m2, mean 28.1 27.6 27.2 25.2 <0.001
Hypertension, % 68.4 64.1 59.5 53.5 0.04
Diabetes, % 28.7 28.1 13.7 9.4 <0.001
Coronary heart disease, % 25.3 12.6 17.9 17.0 0.02
Stroke, % 4.0 6.6 4.2 4.4 0.66
Transient ischemic attack, % 4.0 1.8 4.2 3.1 0.60
Cognitive impairment, % 23.0 22.1 24.3 40.2 0.12
Precise range is not shown due to rounding. N=668. P-value for analyses of variance (ANOVA) or chi2 tests.
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of the relationship by inflammation, these markers were measured in
peripheral blood and so may not have captured the degree of leptin-
induced neuroinflammation in our participants. Macrovascular disease
as another potential causal intermediate also did not contribute to the
relationship though we measured only symptomatic macrovascular
disease; thus subclinical atherosclerosis remains a potential mediator.
Finally, cognitive reserve is a determinant both of leptin (Labad et al.,
2012) and cognitive ability in older age (Opdebeeck et al., 2016), and
an important potential confounder as a result. Here, we showed that the
associations of leptin with cognitive impairment was independent of
education as a proxy of cognitive reserve thus corroborating potential
causal effects.
Several previous studies found that (in those cases, inverse) asso-
ciations of leptin with 5- to 8-year cognitive risk were limited to non-
obese (BMI < 30 kg/m2) (Lieb et al., 2009) or non-overweight/obese
individuals (BMI < 25 kg/m2) (Zeki Al Hazzouri et al., 2013). Due to
this and the close relationship of leptin and adiponectin with BMI, we
not only controlled for BMI but had additionally included interaction
Table 3
Correlations among adipokines and of adipokines with age and body mass index.
Age Body mass index Total adiponectin2 HMW adiponectin sOB-R1
Leptin −0.03 (0.44) 0.51 (< 0.001) −0.07 (0.06) −0.02 (0.60) −0.50 (< 0.001)
sOB-R1 0.09 (0.02) −0.43 (< 0.001) 0.23 (< 0.001) 0.28 (< 0.001) –
HMW adiponectin 0.13 (0.001) −0.24 (< 0.001) 0.77 (< 0.001) – –
Total adiponectin2 0.09 (0.02) −0.24 (< 0.001) – – –
HMW, high molecular weight; sOB-R, soluble leptin receptor.
Values are Spearman rank correlation coefficients (P-values). Analysis n=669, except 1n= 644 and 2n=668; analysis of total adiponectin and sOB-R,n=643.
Table 4
Adjusted odds and 95 % CI of cognitive impairment for quartiles of adipokine concentration, and for continuous adipokine concentration.
h Quartiles of plasma concentration Continuously3
I II III IV Ptrend OR (95 % CI) per 1 SD increment POR
Leptin Model 1 1.0 (Ref) 1.34 (0.81, 2.20) 1.30 (0.77, 2.20) 2.58 (1.45, 4.58) 0.007 1.30 (1.07, 1.57) 0.009
Model 2 1.0 (Ref) 1.35 (0.80, 2.28) 1.39 (0.80, 2.45) 2.86 (1.43, 5.72) 0.02 1.33 (1.05, 1.69) 0.02
sOB-R 1 Model 1 1.0 (Ref) 0.95 (0.58, 1.54) 0.90 (0.55, 1.48) 0.83 (0.50, 1.37) 0.90 0.86 (0.71, 1.04) 0.12
Model 2 1.0 (Ref) 0.94 (0.57, 1.54) 0.91 (0.54, 1.53) 0.85 (0.49, 1.49) 0.95 0.87 (0.71, 1.06) 0.17
Total adiponectin2 Model 1 1.0 (Ref) 0.98 (0.61, 1.56) 0.82 (0.51, 1.32) 0.88 (0.54, 1.42) 0.83 0.90 (0.75, 1.07) 0.21
Model 2 1.0 (Ref) 0.97 (0.60, 1.56) 0.91 (0.56, 1.49) 1.05 (0.63, 1.75) 0.95 0.95 (0.79, 1.15) 0.61
HMW adiponectin Model 1 1.0 (Ref) 0.67 (0.42, 1.07) 0.62 (0.39, 1.01) 0.76 (0.47, 1.24) 0.22 0.98 (0.82, 1.16) 0.80
Model 2 1.0 (Ref) 0.69 (0.42, 1.11) 0.72 (0.44, 1.19) 0.95 (0.57, 1.59) 0.31 1.06 (0.88, 1.27) 0.55
FLI1 Model 1 1.0 (Ref) 1.30 (0.79, 2.14) 1.30 (0.77, 2.20) 1.83 (1.05, 3.19) 0.21 1.11 (0.93, 1.33) 0.24
Model 2 1.0 (Ref) 1.32 (0.78, 2.22) 1.35 (0.77, 2.39) 1.93 (0.98, 3.81) 0.30 1.10 (0.90, 1.34) 0.37
LAR2 Model 1 1.0 (Ref) 0.94 (0.57, 1.53) 1.14 (0.69, 1.89) 1.86 (1.10, 3.16) 0.04 1.28 (1.07, 1.54) 0.008
Model 2 1.0 (Ref) 0.88 (0.53, 1.47) 1.10 (0.63, 1.91) 1.76 (0.93, 3.33) 0.10 1.26 (1.01, 1.57) 0.04
BMI, body mass index; CI. confidence interval; FLI, free leptin index; HMW, high molecular weight; LAR, leptin/adiponectin ratio; SD, standard deviation; sOB-R,
leptin receptor.
Analysis n= 669, except 1n=644 and 2n= 668.
p-value for trend (two-sided) across quartiles is based on the median adipokine concentrations within quartiles, used as a continuous variable and analyzed using the
Wald chi2 statistic.
Model 1: adjusted for age, sex, fasting (and for leptin, sOB-R, FLI, LAR additionally for analysis lab).
Model 2: Model 1+body mass index, diabetes, hypertension, stroke, transient ischemic attack, coronary heart disease.
3adipokines were standardized for these analyses, so that OR estimates show the change in odds of cognitive impairment for each SD increment in adipokine
concentration.
Table 5
Adjusted odds and 95 % CI of cognitive impairment stratified by obesity status, and results for adipokine x BMI interaction terms across total sample.
Obese subgroup (BMI≥ 30 kg/m2) Non-obese subgroup (BMI < 30 kg/m2) Pinteraction
OR (95 % CI) per 1 SD increment P-value OR (95 % CI) per 1 SD increment P-value
Leptin 0.87 (0.60, 1.26) 0.460 2.09 (1.44, 3.02) <0.001 0.002
sOB-R1 1.40 (0.76, 2.57) 0.284 0.78 (0.62, 0.99) 0.04 0.60
Total adiponectin2 0.85 (0.49, 1.49) 0.570 0.96 (0.78, 1.17) 0.65 0.30
HMW adiponectin 1.17 (0.66, 2.06) 0.597 1.04 (0.86, 1.27) 0.67 0.30
FLI1 0.90 (0.68, 1.19) 0.466 1.54 (1.03, 2.30) 0.03 0.05
LAR2 0.95 (0.67, 1.35) 0.761 1.72 (1.23, 2.41) 0.002 0.03
BMI, body mass index; CI, confidence interval; FLI, free leptin index; HMW, high molecular weight; LAR, leptin/adiponectin ratio; sOB-R, leptin receptor.
Analysis n= 669. Of these, n= 142 (21.1 %) in the ‘obese’ group and n=527 (78.8 %) in the ‘non-obese’ group.
1Analysis n=644. Of these, n=137 (21.3 %) in the ‘obese’ group and n=507 (78.7 %) in the ‘non-obese’ group.
2Analysis n=668. Of these, 142 (21.3 %) in the ‘obese’ group and n=526 (78.7 %) in the ‘non-obese’ group.
All analyses adjusted for age, sex, fasting (and for leptin, sOB-R, FLI, LAR additionally for analysis lab), body mass index, diabetes, hypertension, stroke, transient
ischemic attack, coronary heart disease.
Adipokines were standardized, so that OR estimates show the change in odds of cognitive impairment for each SD increment in adipokine.
Interaction terms from analysis of (adipokine x body mass index) in separate logistic regression models of each adipokine and cognitive impairment in total sample.
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terms and also stratified analyses by obesity status. Associations of
leptin with cognitive impairment were restricted to non-obese in-
dividuals (BMI < 30 kg/m2), which further supports our interpretation
of leptin as a direct promoter of cognitive impairment: leptin transport
from circulation across the BBB is in fact compromised in obesity
(Banks et al., 2006), which can account for obesity failing to induce
satiety despite high circulating leptin (Banks et al., 2006) as well as for
an attenuation of correlations of CSF with plasma leptin in obese re-
lative to non-obese individuals (Johnston et al., 2014). We assume that
in our sample participants in the non-obese group were exposed to a
steadily increasing cognitive risk with higher circulating (and therefore
brain) leptin concentration, whereas for obese individuals circulating
leptin did not reflect leptin concentration in the brain, leading to null
findings for that group. Alternatively, analyses of the obese group may
have been limited by reduced statistical power due to low participant
number, though on inspection of effect estimates combined with the
statistical significance of the interaction terms, we deem this possibility
unlikely. We urge readers to interpret the results from these subgroup
analyses with caution nonetheless. Of note, BMI itself was unrelated to
cognitive impairment in our analysis and in a previous investigation of
a subsample of this cohort (Feinkohl et al., 2019) so that a recent report
of leptin as a mediator of the relationship of higher BMI with lower
cognitive function (Smith et al., 2019) was not supported by our data.
Irrespective of the role of leptin in the pathogenesis of cognitive
impairment, we have demonstrated that it has potential as a biomarker
of cognitive impairment and could be used for risk stratification of older
adults. Measurement of total (bound and unbound) leptin appears to
suffice for this purpose. Combined measurement with levels of its re-
ceptor or adiponectin did not add any valuable additional information
over and above leptin.
4.1. Strengths and limitations
Our study has several strengths. We used a large sample of older
adults who were all free of clinical dementia and defined cognitive
impairment from performance on a large battery of cognitive tests using
principal component analysis to account for measurement error. Yet, a
number of limitations should be considered. Because we defined ‘cog-
nitive impairment’ relative to the sample, we are unable to generalize
our findings to clinically relevant cognitive outcomes such as dementia.
Given that blood-based diagnostic biomarkers of dementia are lacked
(Feinkohl et al., 2020; Hampel et al., 2010), further research is needed
in that direction. We used a cross-sectional design and included only
participants of the BioCog cohort who had complete data on adipokines
and cognition. This will have introduced a selection bias; the analysis
sample was unlikely representative of the full BioCog cohort. Because
participants were scheduled for surgery within a few days of providing
these data, our sample was presumably of a relatively low health status
and unlikely representative of the general older population. At the same
time, the surgical nature of the sample is also an asset to our study,
because it allowed recruitment of patients who would otherwise not be
enrolled into a study that required active travel to a study site. Leptin
and sOB-R were measured in two different labs and although we con-
trolled our analysis for this factor, residual confounding by analysis lab
is a possibility. An influence by unmeasured variables too cannot be
ruled out. We ran a large number of statistical analyses thus increasing
the risk of Type I error.
4.2. Future directions
Further research is needed to tease out the beneficial versus detri-
mental effects of leptin on brain function. Separate investigation of
obese and non-obese groups, or, in sufficiently large samples, of un-
derweight, normal weight, overweight and obese groups is advisable.
Long-term prospective studies could further account for reverse caus-
ality of prodromal dementia impacting on adipose tissue mass and,
consequently, adipokine levels, which may also in part drive reports of
reduced cognitive risk in high-leptin individuals in older age. Here, we
used a surgical patient sample. Whether the association of higher leptin
concentration with higher odds of cognitive impairment before surgery
extends to an increased risk of post-operative cognitive dysfunction
(POCD) remain to be explored.
5. Conclusion
In one of the largest studies on adipokine concentration and cog-
nition performed to date, higher plasma leptin concentrations were
associated with increased odds of cognitive impairment and in-
dependently of sociodemographics, vascular risk factors, macrovascular
disease, inflammation, as well as BMI. Underlying mechanisms warrant
further assessment.
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